Our Unique Business Model
The Acuitas business model is unique. As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, our full focus is on refining and improving our LNP for use by our partners.
Supporting partner success is at the heart of everything that we do at Acuitas. We know that when our partners succeed, we succeed.
Our ability to support multiple global partners provides exponential advancement in human health. We are able to collaborate with different partners that are developing vaccines and other therapeutics for traditionally challenging diseases such as HIV, tuberculosis, malaria and cancer. Working with our partners, we are pushing the boundaries of nucleic acid therapeutics for human health. It is an exciting time in life sciences and at Acuitas.
The latest video in our three-part series explains our business model and our dedication to partner success. It features interviews with Abi Coman-Walker, Chief Operating Officer; Miranda Lam, Chief Legal Officer & Senior Director, Business Development; Linda Diano, Head, Strategic Alliance Management; and Jon Le Huray, Director, Analytical and Bioanalytical – along with quite a few appearances of the rest of our team.
We hope you enjoy it!